Abstract
Abstract
Cancer genomic profiling requires a choice between targeted gene panels, whole exome sequencing and whole genome sequencing (W G S). This narrative review appraises W G S as a routine diagnostic test from the pathologist's perspective, with attention to resource-limited health systems. W G S detects small variants, copy number changes, structural variants and mutational signatures in one D N A assay, and programmes in England and the Netherlands show it can be delivered routinely. The same programmes define its limits. In the Dutch W I D E study, W G S failed in 30% of samples, mainly because of low tumour purity, and only 147 of 603 patients with actionable biomarkers started matched therapy; in English paediatric practice, management was unchanged in about 93% of cases. Expressed fusions need R N A confirmation, and low-frequency variants are better detected by deep panels. We found no randomised trial comparing W G S with panel testing, and cost-effectiveness modelling in lung cancer does not favour it. The N H S England National Genomic Test Directory and European Society for Medical Oncology recommendations already limit W G S, or broad sequencing, to defined indications. We propose a five-step, three-tier extension, not yet validated, in which test choice depends on access to matched therapy, indication, specimen and laboratory capability, and each W G S indication has a targeted comparator. In health systems such as India's, where pathology relies on formalin-fixed tissue, testing is largely paid for out of pocket and many patients with a targetable driver go untreated, validated panels, with hub referral of paediatric, acute leukaemia and sarcoma cases for W G S, are a defensible standard.
Introduction
Introduction
Next-generation sequencing (N G S) has moved cancer classification from purely histopathological frameworks towards molecularly defined entities. Three approaches are used clinically (table 1): targeted gene panels, whole exome sequencing (W E S) and whole genome sequencing (W G S).
Reviews of W G S in oncology have largely come from the centres that deliver it, within health systems that have already decided where to use it. N H S England commissions W G S for defined cancer indications, and the European Society for Medical Oncology (E S M O) specifies the tumour types in which broad sequencing is justified. These frameworks do not address how a pathology service without fresh-frozen tissue pathways, an accredited genome laboratory or reimbursed targeted drugs should choose a test. That is the position of many laboratories in low- and middle-income countries, including India.
This review therefore has three aims: to compare the three approaches briefly; to appraise the evidence from routine W G S programmes, including their failures, from the pathologist's perspective; and to propose an indication-led, capability-tiered model for test selection, set out as a table of recommendations (table 2) and a five-step decision algorithm (figure 1).
We searched PubMed for English-language articles published up to 11 November 2026 using combinations of the terms "whole genome sequencing", "whole exome sequencing", "targeted gene panel", "comprehensive genomic profiling", "cancer diagnosis", "clinical implementation", "cost" and "India". We prioritised guidelines, randomised trials, prospective implementation studies, micro-costing studies and large real-world cohorts, and identified further sources from reference lists; 77 sources are cited. As this is a narrative review, we applied no formal inclusion criteria and did not assess risk of bias.

